Rob R. Ruijtenbeek
Corporate Officer/Principal at PamGene International BV
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Patrick van Beneden | M | 62 |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 24 years |
Tim Kievits | M | - |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 25 years |
Theo van der Leij | M | - |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | - |
Mark Wegter | M | 54 |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 24 years |
Rinie van Beuningen | M | - |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 23 years |
Martine Hulselmans | F | - |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bas Xue | M | - |
University of Utrecht
| 6 years |
Mehmet Bulut | M | 54 |
University of Utrecht
| 3 years |
Eveline Speelman | M | - |
University of Utrecht
| 5 years |
Jean Deleage | M | 83 |
PamGene International BV
PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 11 years |
Reinier de Jong | M | - |
University of Utrecht
| 3 years |
David Welch | M | - |
University of Utrecht
| 4 years |
Jakob Hits | M | - |
University of Utrecht
| 7 years |
Rong Guo Qiu | M | 62 |
University of Utrecht
| 3 years |
Robert Emile Hartog | M | - |
University of Utrecht
| 6 years |
Machteld Groeneveld | F | - |
University of Utrecht
| 5 years |
Herbert Schilperoord | M | - |
University of Utrecht
| 5 years |
André van Puijenbroek | M | - |
University of Utrecht
| 3 years |
Marnix van der Feltz | M | - |
University of Utrecht
| 6 years |
Jochem Baalmann | M | - |
University of Utrecht
| 1 years |
Jan Frens van Giessel | M | - |
University of Utrecht
| 5 years |
Judith Bia | F | - |
University of Utrecht
| 4 years |
Robert Kraal | M | 50 |
University of Utrecht
| 1 years |
Michiel van Wissen | M | 41 |
University of Utrecht
| 5 years |
Erik H. van Beers | M | - |
University of Utrecht
| 4 years |
Alexander Ery Wibowo | M | 44 |
University of Utrecht
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
Netherlands | 26 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rob R. Ruijtenbeek
- Personal Network